Press coverage about Myomo (NYSE:MYO) has trended somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Myomo earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.179788825498 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Myomo (NYSE MYO) opened at 7.14 on Thursday. The company’s market capitalization is $43.46 million. The firm has a 50-day moving average price of $7.44 and a 200 day moving average price of $9.29. Myomo has a 52-week low of $5.75 and a 52-week high of $23.20.

Myomo (NYSE:MYO) last posted its earnings results on Monday, August 14th. The company reported ($1.06) EPS for the quarter. The company had revenue of $0.31 million during the quarter.

COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/14/myomo-myo-receives-news-sentiment-rating-of-0-14.html.

Myomo Company Profile

Myomo, Inc is a United States-based medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company’s products help to restore function in individuals with neuromuscular conditions, such as brachial plexus injury, spinal cord injury, multiple sclerosis and stroke.

Receive News & Stock Ratings for Myomo Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo Inc and related stocks with our FREE daily email newsletter.